Unaudited Financial Results of the Company along with Limited Review Report for the quarter and nine months ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts more than Nifty Microcap 250 and 4.9 pts more than its Other Financial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Roselabs Finance Limited submitted its unaudited financial results for the quarter and nine months ended December 31, 2025, approved at the Board meeting on January 20, 2026. Revenue from operations stood at Rs. 120.75 lakhs for both Q3 FY26 and the 9M FY26 period, up from Rs. 70.91 lakhs and Rs. 72.59 lakhs respectively in the year-ago periods, reflecting strong top-line growth. However, the company continued to post losses, with a Q3 loss before tax of Rs. 3.67 lakhs (vs Rs. 10.84 lakhs loss in Q3 FY25) and a 9M FY26 loss of Rs. 14.33 lakhs (vs Rs. 24.63 lakhs in 9M FY25), showing a narrowing trend. Statutory auditor MSKA & Associates LLP issued an unmodified (clean) limited review report with no qualifications or emphasis of matter. Other equity remains negative at Rs. (1,472.76) lakhs, indicating accumulated losses exceed paid-up capital.
The sharp jump in revenue is a positive signal, but the company is still loss-making and carries negative net worth, so shareholders should watch for sustained profitability rather than just top-line growth. The clean auditor opinion is reassuring, but the weak equity base remains a structural concern.